Spherix Inc. said its D-tagatose, a product originally developed as a reduced-calorie sugar substitute, hit statistical significance in a Phase III trial in Type II diabetes, news that sent shares of the Bethesda, Md.-based firm up 33 percent in early trading. (BioWorld Today) Read More
